These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38476237)

  • 21. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
    Roblin X; Williet N; Boschetti G; Phelip JM; Del Tedesco E; Berger AE; Vedrines P; Duru G; Peyrin-Biroulet L; Nancey S; Flourie B; Paul S
    Gut; 2020 Jul; 69(7):1206-1212. PubMed ID: 31980448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
    Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trough Concentration Response in Infliximab and Adalimumab Treated Children With Inflammatory Bowel Disease Following Treatment Adjustment: A Pharmacokinetic Model.
    Levy R; Matar M; Zvuloni M; Shamir R; Assa A
    J Pediatr Gastroenterol Nutr; 2023 May; 76(5):576-581. PubMed ID: 37083732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum γ-globulin and albumin concentrations predict secondary loss of response to anti-TNFα in inflammatory bowel disease patients.
    Schoenefuss F; Hoffmann P
    Eur J Gastroenterol Hepatol; 2019 Dec; 31(12):1563-1568. PubMed ID: 31567711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
    Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
    Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease.
    Juncadella A; Papamichael K; Vaughn BP; Cheifetz AS
    Dig Dis Sci; 2018 Nov; 63(11):3067-3073. PubMed ID: 30006816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
    Papamichael K; Stocco G; Ruiz Del Agua A
    Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.
    Steenholdt C; Bendtzen K; Brynskov J; Ainsworth MA
    Inflamm Bowel Dis; 2016 Aug; 22(8):1999-2015. PubMed ID: 27135483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
    Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
    J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of axial spondyloarthritis after one year of anti-tumor necrosis factor therapy among patients with inflammatory bowel diseases.
    Dalal RS; Ermann J; Carlin A; Mitri J; Allegretti JR
    Clin Rheumatol; 2023 Nov; 42(11):3001-3006. PubMed ID: 37428414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents.
    Molander P; Färkkilä M; Kemppainen H; Blomster T; Jussila A; Mustonen H; Sipponen T
    Scand J Gastroenterol; 2017 Mar; 52(3):284-290. PubMed ID: 27806638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physiologically-Based Pharmacokinetic Modeling of Anti-Tumor Necrosis Factor Agents for Inflammatory Bowel Disease Patients to Predict the Withdrawal Time in Pregnancy and Vaccine Time in Infants.
    Chen J; Lin R; Guo G; Wu W; Ke M; Ke C; Huang P; Lin C
    Clin Pharmacol Ther; 2023 Dec; 114(6):1254-1263. PubMed ID: 37620249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.
    Gil-Candel M; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Iniesta-Navalón C
    Int J Clin Pharm; 2020 Apr; 42(2):500-507. PubMed ID: 32006141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease.
    Grišić AM; Dorn-Rasmussen M; Ungar B; Brynskov J; Ilvemark JFKF; Bolstad N; Warren DJ; Ainsworth MA; Huisinga W; Ben-Horin S; Kloft C; Steenholdt C
    United European Gastroenterol J; 2021 Feb; 9(1):91-101. PubMed ID: 33079627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel Disease.
    Doherty J; Ryan AW; Quinn E; Conroy J; Dolan J; Corcoran R; Hara FO; Cullen G; Sheridan J; Bailey Y; Dunne C; Hartery K; McNamara D; Doherty GA; Kevans D
    Inflamm Bowel Dis; 2024 Jun; ():. PubMed ID: 38937958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.
    Wilson A; Peel C; Wang Q; Pananos AD; Kim RB
    Aliment Pharmacol Ther; 2020 Feb; 51(3):356-363. PubMed ID: 31650614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy.
    Miler M; Nikolac Gabaj N; Ćelap I; Grazio S; Tomašić V; Bišćanin A; Mitrović J; Đerek L; Morović-Vergles J; Vrkić N; Štefanović M
    Rheumatol Int; 2021 Dec; 41(12):2195-2203. PubMed ID: 34623480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Clinical Outcomes in Pediatric Patients with Ileocolonic Crohn Disease Treated with Infliximab Versus Adalimumab.
    Fanous E; Marshanski T; Tal N; Matar M; Weintraub Y; Shamir R; Shouval DS
    J Pediatr Gastroenterol Nutr; 2023 Sep; 77(3):358-365. PubMed ID: 37276146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.